PF-06817024

N/A

Report date: 2026/03/09 20:02:04

Base Information

Drug NamePF-06817024
Drug Alias Nameanti-IL-33 mAbPF-06817024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-33 inhibitors
TargetsInterleukin-33
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A